tiprankstipranks
Advertisement
Advertisement

IMRX Stock Latest News

3 Best Stocks to Buy Now, 3/10/2026, According to Top Analysts
Market News3 Best Stocks to Buy Now, 3/10/2026, According to Top Analysts
25d ago
EVAX
IMRX
3 Best Stocks to Buy Today, 3/9/2026, According to Top Analysts
PremiumMarket News
3 Best Stocks to Buy Today, 3/9/2026, According to Top Analysts
27d ago
MWH
AKTS
Immuneering price target lowered to $12 from $13 at Piper Sandler
PremiumThe Fly
Immuneering price target lowered to $12 from $13 at Piper Sandler
27d ago
IMRX
Advancing Atebimetinib Pipeline and Strong Cash Runway Underpin Buy Rating on Immuneering
PremiumRatings
Advancing Atebimetinib Pipeline and Strong Cash Runway Underpin Buy Rating on Immuneering
27d ago
IMRX
Midday Fly By: Rising oil prices, falling employment sink stocks
PremiumThe Fly
Midday Fly By: Rising oil prices, falling employment sink stocks
30d ago
BA
BX
Immuneering reports Q4 EPS (18), consensus (31c)
PremiumThe FlyImmuneering reports Q4 EPS (18), consensus (31c)
30d ago
IMRX
Immuneering sees cash runway into 2029
Premium
The Fly
Immuneering sees cash runway into 2029
30d ago
IMRX
Immuneering updated 12-month data for atebimetinib ‘encouraging,’ says Leerink
Premium
The Fly
Immuneering updated 12-month data for atebimetinib ‘encouraging,’ says Leerink
3M ago
IMRX
RVMD
Midday Fly By: Defense stocks surge on Trump budget request
PremiumThe Fly
Midday Fly By: Defense stocks surge on Trump budget request
3M ago
F
AA
Immuneering: Phase 2a Strength of Atebimetinib in First-Line Pancreatic Cancer Supports Buy Rating Despite Competitive Overhang
PremiumRatings
Immuneering: Phase 2a Strength of Atebimetinib in First-Line Pancreatic Cancer Supports Buy Rating Despite Competitive Overhang
3M ago
IMRX
Closing Bell Movers: Defense stocks surge on Trump military budget comments
PremiumThe Fly
Closing Bell Movers: Defense stocks surge on Trump military budget comments
3M ago
FC
GD
Immuneering reports ‘positive’ survival, safety data from atebimetinib trial
PremiumThe Fly
Immuneering reports ‘positive’ survival, safety data from atebimetinib trial
3M ago
IMRX
Immuneering Reports Strong Phase 2a Pancreatic Cancer Survival Data
PremiumCompany AnnouncementsImmuneering Reports Strong Phase 2a Pancreatic Cancer Survival Data
3M ago
8K
IMRX
Immuneering management to meet with Oppenheimer
Premium
The Fly
Immuneering management to meet with Oppenheimer
3M ago
IMRX
Immuneering to announce OS data from Phase 2a trial of atebimetinib, mGnP
Premium
The Fly
Immuneering to announce OS data from Phase 2a trial of atebimetinib, mGnP
3M ago
IMRX
Immuneering on track to dose first patient in pancreatic cancer trial in 2026
PremiumThe Fly
Immuneering on track to dose first patient in pancreatic cancer trial in 2026
4M ago
IMRX
Immuneering to be added to the Nasdaq Biotechnology Index
PremiumThe Fly
Immuneering to be added to the Nasdaq Biotechnology Index
4M ago
IMRX
Immuneering Corp. Shines in Positive Earnings Call
PremiumCompany Announcements
Immuneering Corp. Shines in Positive Earnings Call
5M ago
IMRX
Promising Potential of Immuneering’s Atebimetinib: Analyst Recommends ‘Buy’ Rating
PremiumRatings
Promising Potential of Immuneering’s Atebimetinib: Analyst Recommends ‘Buy’ Rating
5M ago
IMRX
Immuneering Corp. Reports Strong Q3 2025 Progress
PremiumCompany AnnouncementsImmuneering Corp. Reports Strong Q3 2025 Progress
5M ago
IMRX
Immuneering reports Q3 EPS (38c), consensus (39c)
Premium
The Fly
Immuneering reports Q3 EPS (38c), consensus (39c)
5M ago
IMRX
Immuneering expects cash to fund operations into 2029
Premium
The Fly
Immuneering expects cash to fund operations into 2029
5M ago
IMRX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >